Car T-Cell Therapy Market Size to grow by USD 3027.1 million between 2024-2028
The Car T-Cell Therapy Market is segmented by End-user (Hospitals and Cancer treatment centers), Type (CD19, CD22, BCMA, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW)). As per the Global Forecast research report 2024-2028 published by Technavio, the market size is estimated to grow by USD 3027.1 million, at a CAGR of 16.83% during the forecast period. There are several companies that are contributing to the market as per this report. Rising number of product approvals and clinical trials related to CAR T- cell therapy .
By End-user, the Hospitals segment is projected to dominate the market size in 2024
In the global CAR T-cell therapy market landscape, hospitals emerge as the leading segment due to their pivotal role as key end-users. Hospitals provide essential infrastructure, medical expertise, and resources for CAR T-cell therapy administration. Specialized oncology departments or treatment centers within hospitals ensure eligible patients receive these advanced therapies. Healthcare professionals, including oncologists, hematologists, and nurses, oversee treatment processes, ensuring patient safety and monitoring therapy responses. Hospitals play a crucial role in patient identification for CAR T-cell therapy eligibility.
For insights on company offerings- Request a sample report!
By Type, CD19 segment is expected to hold the largest market size for the year 2024
The CD19 protein, expressed on B-cells, has revolutionized the cancer treatment landscape through CAR T-cell therapies. These innovative treatments, which involve genetically modifying T-cells to target CD19, have demonstrated significant success in combating B-cell malignancies, including B-ALL and DLBCL. For businesses in the immunotherapy sector, the CD19 CAR T-cell therapy market represents a lucrative opportunity, particularly for those addressing the unmet needs of chemotherapy-resistant patients with hematologic malignancies and solid tumors.
Why is North America forecasted to hold the largest regional market size in 2024?
The Car T-Cell Therapy Market represents a significant business opportunity in the healthcare sector, driven by advancements in immunotherapy and cellular technology. This market involves the production and application of chimeric antigen receptor (CAR) T-cells, genetically engineered immune cells, to target and eliminate cancer cells. Companies are investing heavily in research and development to bring innovative CAR T-cell therapies to market, addressing unmet medical needs and generating substantial revenue growth.
To access the valuable insights - Download the Free Sample Report
Research Analysis Overview
In the realm of precision medicine, Car T-cell therapies have emerged as a revolutionary approach to tailoring treatments for various cancer types, including lymphoma and leukemia. These therapies involve engineering a patient's own T-cells to recognize and attack cancer cells. Companies such as Celgene Corporation and Juno Therapeutics are at the forefront of this innovation in cancer treatment and blood cancer treatment. The prevalence of cancer in the patient population continues to rise, necessitating advancements in healthcare infrastructure and public awareness. Reimbursement policies are a critical factor in the market growth of Car T-cell therapies, as their high cost requires careful consideration. The incidence of cancer, particularly blood cancers, presents a significant opportunity for the Car T-cell therapy market to make a substantial impact on cancer treatments. Car T-cell therapies represent a promising development in the field of cancer treatment, offering a potential cure for some patients where traditional methods have failed. As research and development continue, we can expect to see further advancements and improvements in the efficacy and accessibility of these therapies.
Market Research Overview
In the dynamic landscape of the global healthcare industry, the Car T-Cell Therapy Market holds significant potential for growth. According to market analysis by Technavio, this market is driven by several key factors, including the increasing geriatric population. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to surpass 60 years old. This demographic shift presents a substantial opportunity for Car T-Cell Therapy, given its potential to address age-related health concerns. - The Car T-Cell Therapy Market is experiencing significant growth, fueled by the . Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/